Reviewing the inter partes review

The establishment of the US Patent Trial and Appeal Board (PTAB) in 2012 changed the game for patent owners. And while life science patents have not always been under the spotlight, recent trends suggest more such patents are being reviewed than ever before.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

mRNA litigation: Who’s winning, who’s filing, and what’s next

25 March 2026 As the world moves past the pandemic, a massive legal struggle over the future of mRNA technology is just hitting its stride. LSIPR visualises the litigation defining the next era.

Careers

Dechert boosts litigation bench with partner duo

25 March 2026 Two senior hires from a rival firm bring litigation expertise across life sciences and tech disputes.

Europe

UK court deals blow to Spanish pharma’s SPC bid for contraceptive

24 March 2026 The drugmaker’s attempt to extend protection for a fast-growing oestrogen-free contraceptive ran into a landmark EU ruling, with the court not persuaded to read it narrowly.

More features

mRNA litigation: Who’s winning, who’s filing, and what’s next

Dechert boosts litigation bench with partner duo

UK court deals blow to Spanish pharma’s SPC bid for contraceptive

EPO reports record patent filings, but pharma and biotech lag

Part II: The race to replace semaglutide heats up

Part I: Ozempic goes generic as Novo’s key patent expires

Masimo convinces judge that Apple took secrets—but it’s not enough

Sandoz strikes fresh biosimilar deal with South Korean biotech

Reviewing the inter partes review

More on this story

Editor's picks

Editor's picks

More features